BioStem Technologies has launched its Amnion Division, BioStem Life Sciences, to develop and market regenerative and therapeutic biologics utilizing human placental tissue allografts for multiple sectors of healthcare.  The established management team has an extensive background of successfully developing, processing, and selling minimally-manipulated Amniotic Tissue products within the U.S., including the likes of amniotic and chorion products, flowable allografts’, and wound care products....